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The new human coronavirus that emerged in Wuhan, Central China, in 
December 2019, has been named SARS-CoV-2 by the International Coronavirus 
Study Group. This coronavirus (CoV) that has already been extended to 171 
countries, has a sequence identity higher than 80% with the SARS-CoV that 
emerged in Guandong province of South East China in 2002. This novel virus 
SARS-CoV-2 is causing a pandemic, certainly the most important one in the 
recent decades, as it has already affected 491,623 people (as of March 26th, 
2020; source: John Hopkins University, Coronavirus COVID-19 Global Cases by 
the Center for Systems Science and Engineering), of which 22,169 have died in 
around four months. During the first phase of the pandemic 80% of these cases 
(81,054) took place in China, but now European countries, especially Italy, Spain 
and Germany, and also USA and Iran, are taking the lead in the list of new 
infected people per day. 
 
SARS-CoV-2 causes a mild pathology in 80% of infected patients, 14% develop 
severe disease, and 6% become critically ill. The virus may cause pneumonia 
associated with fever, headache, and respiratory difficulty, that may evolve to 
exacerbated lung inflammation, edema and death in around 2% of infected 
patients. Older adults, particularly those that have associated additional 
pathologies, such as diabetes, cardiovascular disease or additional respiratory 
complications, are more susceptible of having a drastic outcome, although 
younger persons with ages above 35 years, sporadically also have a negative 
outcome. 
 
At present, seven coronaviruses infecting human beings are known. Four of them 
cause a midwinter common cold, and almost all adults have already been 
infected by one or more of them. In contrast, the other three human coronaviruses 
(that is SARS-CoV that emerged in the South East of China in 2002, MERS-CoV 
that emerged in the Arabian Peninsula in 2012, and the recently emerged SARS-
CoV-2 that was identified for the first time in Wuhan) caused the death in 10%, 
35% and around 2% of the infected people, respectively. The three deadly 
coronaviruses for humans have affected for the moment to 8,000, 2,600 and 
491,623 confirmed patients, respectively, showing that they have had a high 
impact in human population, particularly the SARS-CoV-2. Nevertheless, 
epidemiologists consider that the real number of infected persons is several folds 
higher. 
 
Position Paper - Enjuanes, Sola & Zúñiga: Novel Human Pathogenic Coronavirus SARS-CoV-2 
2/5 
 
During their replication, RNA viruses introduce mistakes into their genome 
(around one for each 10,000 nucleotides added), leading to the generation of a 
huge amount of new virus mutants, some of them able to cross species barrier 
and infect humans. Most likely this has caused the epidemic outbreak at the end 
of 2019. Unfortunately, in this epidemic the vector that has served as an 
intermediate vehicle amplifying the virus before being transmitted from bats to 
humans has not been identified. In fact, although games, snakes and pangolins 
have been suggested as the intermediate host, the scientific evidence provided 
has not been considered solid. Based on previous experience on coronaviruses 
crossing species barriers, and on viral genome sequence data, it has been 
postulated that an intermediate vector between bats and humans, most likely 
another mammal, has passed the virus. This statement is based on the 
observation that although there are many SARS-CoV-like viruses in bats, their 
genome sequence identity with the new Wuhan virus is lower than 96%, and it 
would have been needed the reiterated growth of this virus through an 
intermediate vector to evolve their sequence to that of SARS-CoV-2. The direct 
jump of a virus from bats to humans is considered unlikely, because in December 
of 2019 bats were in their hibernation period in the Wuhan area, and because the 
known sequences of bat coronaviruses are still significantly different from that of 
the SARS-CoV-2.  
 
A behavior of the Wuhan coronavirus which makes the control of this epidemic 
harder, is that a large proportion of the infected patients undergo a long 
incubation period that normally ranges from 2 to 14 days (exceptionally up to 28 
days), without showing clinical signs of disease, facilitating the dissemination of 
the virus. In addition, 14% of the infected persons, after recovery and being 
declared free of the virus, apparently become again positive in the polymerase 
chain reaction (PCR) that amplifies the viral genome. An explanation for the 
apparent reappearance of SARS-CoV-2 in some patients, which is getting higher 
support, is that the apparently cured patients did not fully cleaned all the virus 
from their bodies. In fact, as a precaution it has been suggested testing recovered 
patients at intervals of seven, 14 and 21 days after being considered clean, using 
similar biological samples. The seeming reappearance of the virus could also 
have been possible if the virus would have antigenically evolved in order to evade 
the immune response; this seems unlikely in view of the high virus sequence 
conservation, particularly in the domains of the S protein eliciting neutralizing 
antibodies. An alternative possibility postulated is the induction by the virus of a 
relatively weak immune response. The generation of a humoral immune 
response by SARS-CoV-2 has been demonstrated in macaques, what justifies 
the recovery of the majority of the patients. However, more detailed studies on 
the humoral and cellular responses elicited by the Wuhan virus are urgently 
needed, and also the identification of viral genes that may suppress the immune 
response induced by SARS-CoV-2.  
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On the positive side, diagnostic kits based on PCR which allow to specifically 
determine SARS-CoV-2 nucleic acid presence within 3-4 hours have been 
developed, thanks to the prompt release of virus sequence by Chinese scientist. 
Furthermore, kits based on serological analysis providing a reply in 15 minutes 
are already in place.  
 
Nowadays, more than 60 CoV treatments are in development, including 
antivirals, antibodies and vaccines. In fact, a collection of antivirals is already 
being tested in clinical trials. Among those marketed by strong multinational 
companies, one heading the race is Remdesivir developed by Gilead. Another 
treatment in the top category is AbbVie’s Kaletra, also marketed as Aluvia, 
(Lopinavir/Ritonavir), which received a low level report on March 21st, 2020. More 
recently Favipiravir, marketed by Fujifilm as Avigan, among others has emerged 
as a new candidate. Another promising antiviral under study, with a well found 
scientific bases is Aplidin, which inhibits the growth of human CoV in infected 
cells at nanomolar concentrations. This antiviral is moving to clinical trials, 
launched by Pharmamar (Spain). 
 
In terms of vaccines, there are many potential types, including those based: (i) 
on a single viral protein, preferentially the Spike (S) protein of the virus or the S1 
subunit (globular domain, including the receptor binding site) of the novel 
coronavirus in combination with an adjuvant; (ii) on the expression of S protein 
using already developed viral vectors such as adenovirus 5, the Chinese vaccine 
that seems one of the most advanced ones; (iii) on Moderna’s company and the 
NIAID headed by Antony Fauci, based on a messenger RNA coding for S protein 
(mRNA-1273); (iv) on MVA poxvirus vectors expressing S protein under 
development by Mariano Esteban’s laboratory at the National Center of 
Biotechnology (CNB-CSIC, Madrid).  
 
Alternatively, in our laboratory of the CNB-CSIC we are constructing SARS-CoV-
2 RNAs as vaccine candidates. These RNAs encoding the viral antigen elicited a 
protective immune response. Our laboratory has constructed a full-length copy of 
the SARS-CoV-2 genome. Development of this vaccine candidate is based on 
previously engineered vaccines for SARS- and MERS-CoVs that provided 100% 
protection in experimental animal models (humanized transgenic mice) and are 
ready for their evaluation in clinical trials. 
  
The number of new SARS-CoV-2 cases in China has been constantly decreasing 
and as of March 22st, 2020, only imported cases are being reported. On the other 
side, it is clear that reduction in the number of new infections in China has been 
partially shadowed by the increase in the number of cases in other countries such 
as Italy, Spain, Korea, Japan, Iran, and the States, to the point that at present the 
number of deaths in Italy (7,503 as of March 26th, 2020) has surpassed those in 
China (3,288). A key question is how this epidemic will evolve next. World Health 
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Organization (WHO) experts such as Maria Van Kerkhove, who heads the 
WHO’s emerging diseases and Zoonoses unit, and has recently visited China 
with an expert mission for two weeks, has concluded that, in fact ”it seems that 
people shed more (virus) in the early phases rather than the late period of 
disease.” That being the case, it will be much more difficult to break the chains of 
transmission and stop the virus. 
  
Overall, data have shown that it is possible to control the epidemics in a densely 
populated country like China with high effort and discipline. Now a similar strategy 
is being followed in European countries. Fortunately, in the majority of the 
Chinese population affected by the Wuhan virus, the largest proportion of the 
patients (more than 98%) has elicited an immune response able to control virus 
progression and, in general, only those elderly adults infected by the Wuhan 
virus, with additional medical problems, deeply suffered from the Wuhan virus 
infection. Certainly, this important part of the population, soon could receive 
immune therapy by using serum collected from recovered patients. In addition, 
this therapeutic approach could soon be expanded with the application of novel 
monoclonal antibodies neutralizing SARS-CoV-2 that are under development. 
Although viruses developed their own strategies to invade human beings, the 
History of Medicine has shown that the battle between virus and host in general 
ends with the elimination of the virus. 
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